Effect of tirzepatide on oxidative stress and glucose variability in patients with type 2 diabetes mellitus

INTERVENTION: Continue GLP‐1 receptor agonists (regular dose) or switch to tirzepatide. Participants in the tirzepatide group follow an escalation regimen of 5mg tirzepatide once weekly (maintenance dose reached after 4 weeks of 2.5 mg tirzepatide once weekly). CONDITION: type 2 diabetes PRIMARY OUTCOME: The primary end point was d‐ROMs change from baseline after completing 24 weeks of treatment intervention. SECONDARY OUTCOME: 1) The change in glucose variability at 24 weeks from baseline; 2) Glucose metabolism index, lipid metabolism index, Renal function, liver function; 3) Eating Behavior Questionnaire and DTSQ; 4) Blood pressure, pulse, weight INCLUSION CRITERIA: a diagnosis of type 2 diabetes mellitus 1) HbA1c 7.0% or more 2) Patients who were treated with regular doses of weekly GLP‐1 receptor agonists at least for 12 weeks 3) BMI >= 23 4) written informed consent 5) 20 years and over